Skip to main content
Delfa

← All assets

high CBD/low THC

1 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

1

Ongoing

1

Recruiting

0

Completed

0

Sites

1

Countries

1

Endpoints

11

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 11 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Early Phase 1
1

Trials by status

Active, not recruiting
1

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Behavior / neuropsychiatric
6
Caregiver / quality of life
2
Safety / tolerability / PK
2
Global cognition
1

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 4 of 11 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Neuropsychiatric Inventory (NPI)Behavior

3

Mini-Mental State Examination (MMSE)Cognition

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

1 of 1

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
CBDCannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

high CBD/low THC

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Alzheimer's diseaseEarly Ph 1Active, not recruiting1Dec 2026-

Showing 1-1 of 1 trials